Trending stocks and marketinsights, made visual.
Data-driven insights into stocks and investing themes. Our visual newsletter takes 5 minutes to read and it’s completely free.

Stories
Robots Need Muscles
Muse Beat ChatGPT's Mobile Launch
Mortgage Rates Are Back Above 7%
Oil's Hormuz Premium Is Leaking Out
Kirkland Is a $90B Brand
AMD Joins the $1T Club
Public AI Models Keep Climbing the Compute Curve
AI Compute Has a Price Board
Stock Ideas
View all ideasManhattan Associates Inc
Manhattan Associates pairs accelerating revenue growth with an established Stage 2 technical uptrend, making it a timely leader in enterprise logistics and vertical software solutions.
Enterprise & Vertical SoftwareMedpace Holdings, Inc.
Medpace, a clinical research services leader, combines consistent double-digit revenue growth and high institutional ownership, making it a timely leader in Life Science Tools & CDMO.
Life Science Tools & CDMOArgenx Se
Argenx's validated Stage 1→2 breakout, reclaimed 200-day trend, and substantial institutional ownership position it as a timely technical leader within Biotech Therapeutics with improving relative strength.
Biotech TherapeuticsBio-Rad Laboratories, Inc.
Bio‑Rad is a leading life‑science tools company with steady quarterly revenue, heavy institutional ownership, and recent strong relative performance versus the S&P, positioning it as a timely theme leader.
Life Science Tools & CDMOBruker Corp
Bruker is positioned as a life-science tools leader with accelerating revenue, a confirmed uptrend, and heavy institutional sponsorship that has driven strong relative performance versus the S&P.
Life Science Tools & CDMOF5, Inc.
F5 is a cybersecurity-focused application delivery and security vendor with recent year-over-year revenue gains, an established technical uptrend, and above-market relative strength versus the S&P 500.
CybersecurityMarket insights
View all insightsDemand and pricing softened further
Management signaled that the housing market deteriorated after the prior call, with both demand and pricing under greater pressure. That implies a tougher near-term backdrop for builders competing in the same affordability-sensitive markets.
Read insight →Built-to-order mix improved backlog visibility
KB Home’s higher built-to-order mix supports better visibility into future deliveries even as the market stays difficult. For the sector, that suggests disciplined order conversion can partially offset softer demand.
Read insight →Margins pressured by pricing competition
The company linked lower margin expectations to pricing pressure, higher costs, and a more competitive Southern California market. That is a clear read-through for homebuilders and related suppliers that depend on stable pricing to preserve margin.
Read insight →Market insights, made visual.
Get data-driven insights into stocks and investing themes in a free newsletter that takes 5 minutes to read.